Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing cases of bile duct cancer globally
3.2.1.2 Rising awareness and early detection campaigns
3.2.1.3 Development of targeted therapies
3.2.1.4 Growing geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment costs
3.2.2.2 Late-stage diagnosis
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Million)
5.1 Key trends
5.2 Extrahepatic bile duct cancer (eCCA)
5.3 Intrahepatic bile duct cancer (iCCA)
Chapter 6 Market Estimates and Forecast, By Treatment, 2018 – 2032 ($ Million)
6.1 Key trends
6.2 Surgery
6.3 Chemotherapy
6.4 Radiation therapy
6.5 Targeted therapy
6.6 Immunotherapy
Chapter 7 Market Estimates and Forecast, By Treatment Provider, 2018 – 2032 ($ Million)
7.1 Key trends
7.2 Hospitals
7.3 Oncology centers & specialty clinics
7.4 Ambulatory surgical centers (ASCs)
Chapter 8 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Eli Lilly and Company
9.3 F. Hoffmann-La Roche AG
9.4 Fresenius SE & Co. KGaA
9.5 Genentech, Inc.
9.6 GlaxoSmithKline plc.
9.7 Incyte Corporation
9.8 Merck & Co., Inc.
9.9 Pfizer Inc.
9.10 QED Therapeutics
